Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)
Go back to Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)| PROSENSA HOLD (NASDAQ: RNA) | Delayed: 12.37 -0.06 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.43 | 52 Week High | $22.80 | |||
| Open | $12.43 | 52 Week Low | $4.12 | |||
| Day High | $12.47 | P/E | N/A | |||
| Day Low | $12.16 | EPS | $0.00 | |||
| Volume | 103,635 | |||||
